Shekarian Tala, Ritz Marie-Françoise, Hogan Sabrina, Martins Tomás A, Schmassmann Philip, Gerber Alexandra, Roux Julien, Kaymak Deniz, Durano Célia, Burger Bettina, Matter Matthias, Hutter Gregor
Brain Tumor Immunotherapy and Biology Laboratory, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
Bioinformatics Core Facility, Department of Biomedicine, University of Basel, Basel, Switzerland.
J Neuropathol Exp Neurol. 2025 Jan 1;84(1):45-58. doi: 10.1093/jnen/nlae108.
Glioblastoma (GBM) is a lethal brain tumor without effective treatment options. This study aimed to characterize longitudinal tumor changes in order to find potentially actionable targets to prevent GBM relapse. We extracted RNA and proteins from fresh frozen tumor samples from patient-matched IDHwt WHO grade 4 primary (pGBM) and recurrent (rGBM) tumors for transcriptomics and proteomics analysis. A tissue microarray containing paired tumor samples was processed for spatial transcriptomics analysis. Differentially expressed genes and proteins between pGBM and rGBM were involved in synapse development and myelination. By categorizing patients into short (STTR) and long (LTTR) time-to-lapse, we identified genes/proteins whose expression levels positively or negatively correlated with TTR. In rGBM, expressions of Fcγ receptors (FCGRs) and complement system genes were negatively correlated with TTR, whereas expression of genes involved in DNA methylation was positively correlated with TTR. Spatial transcriptomics of the tumor cells showed enrichment of oligodendrocytes in rGBM. Besides, we observed changes in the myeloid compartment such as a switch from quiescent to activated microglia and an enrichment in B and T cells in rGBM with STTR. Our results uncover a role for activated microglia/macrophages in GBM recurrence and suggest that interfering with these cells may hinder GBM relapse.
Acta Neuropathol Commun. 2023-7-31
Clin Cancer Res. 2018-12-4
Lab Invest. 2022-7
Proteomics Clin Appl. 2024-5
Cancer Cell. 2024-7-8
Cancer Cell. 2024-3-11
Nature. 2023-11
Neuro Oncol. 2023-3-14